CU20190104A7 - Formulación estable del anticuerpo nimotuzumab - Google Patents

Formulación estable del anticuerpo nimotuzumab

Info

Publication number
CU20190104A7
CU20190104A7 CU2019000104A CU20190104A CU20190104A7 CU 20190104 A7 CU20190104 A7 CU 20190104A7 CU 2019000104 A CU2019000104 A CU 2019000104A CU 20190104 A CU20190104 A CU 20190104A CU 20190104 A7 CU20190104 A7 CU 20190104A7
Authority
CU
Cuba
Prior art keywords
stable formulation
nimotuzumab
antibody
nimotuzumab antibody
stable
Prior art date
Application number
CU2019000104A
Other languages
English (en)
Inventor
Ayo Tammy Boggiano
Vitloch Adolfo Castillo
Arias Mercedes Cedeño
Sáez Olga Lidea Fernández
Terrero Yaiko Saddan Hernández
Monzón Kalet León
De La Luz Hernández Kathya Rashida
Tomás Pompa Julio Felipe Santo
Original Assignee
Ct Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Inmunologia Molecular filed Critical Ct Inmunologia Molecular
Priority to CU2019000104A priority Critical patent/CU20190104A7/es
Priority to PCT/CU2020/050007 priority patent/WO2021121444A2/es
Priority to US17/786,094 priority patent/US20230018364A1/en
Priority to CN202080088100.8A priority patent/CN114867468A/zh
Priority to AU2020409887A priority patent/AU2020409887B2/en
Priority to EP20903282.0A priority patent/EP4079294A2/en
Priority to MX2022007509A priority patent/MX2022007509A/es
Priority to JP2022536924A priority patent/JP7796646B2/ja
Priority to KR1020227024674A priority patent/KR20220119091A/ko
Priority to BR112022010488A priority patent/BR112022010488A2/pt
Priority to CA3163630A priority patent/CA3163630A1/en
Publication of CU20190104A7 publication Critical patent/CU20190104A7/es
Priority to CONC2022/0009693A priority patent/CO2022009693A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

<p>La presente invención se relaciona con las ramas de Ia Biotecnología y Ia Medicina y describe formulaciones farmacéuticas de alta concentración que comprenden al anticuerpo monoclonal humanizado nimotuzumab en un rango de concentración entre 50 a 200 mg/mL. Los bajos valores de viscosidad de dichas soluciones permiten su empleo por vía subcutánea o intramuscular en el tratamiento del cáncer. Estas formulaciones son estables tanto en sus formas líquidas como liofilizadas.<br /> </p>
CU2019000104A 2019-12-17 2019-12-17 Formulación estable del anticuerpo nimotuzumab CU20190104A7 (es)

Priority Applications (12)

Application Number Priority Date Filing Date Title
CU2019000104A CU20190104A7 (es) 2019-12-17 2019-12-17 Formulación estable del anticuerpo nimotuzumab
EP20903282.0A EP4079294A2 (en) 2019-12-17 2020-12-10 Stable and highly concentrated formulation of the antibody nimotuzumab
US17/786,094 US20230018364A1 (en) 2019-12-17 2020-12-10 Stable high-concentration forumulation of nimotuzumab antibody
CN202080088100.8A CN114867468A (zh) 2019-12-17 2020-12-10 尼妥珠单抗的稳定和高浓度制剂
AU2020409887A AU2020409887B2 (en) 2019-12-17 2020-12-10 Stable and highly concentrated formulation of the antibody nimotuzumab
PCT/CU2020/050007 WO2021121444A2 (es) 2019-12-17 2020-12-10 Formulación estable y de alta concentración del anticuerpo nimotuzumab
MX2022007509A MX2022007509A (es) 2019-12-17 2020-12-10 Formulacion estable y de alta concentracion del anticuerpo nimotuzumab.
JP2022536924A JP7796646B2 (ja) 2019-12-17 2020-12-10 抗体ニモツズマブの安定で高濃度の製剤
KR1020227024674A KR20220119091A (ko) 2019-12-17 2020-12-10 항체 니모투주맙(nimotuzumab)의 안정한 고농축 제형
BR112022010488A BR112022010488A2 (pt) 2019-12-17 2020-12-10 Formulação farmacêutica, uso da formulação farmacêutica, e, método para tratamento de um paciente
CA3163630A CA3163630A1 (en) 2019-12-17 2020-12-10 Stable and highly concentrated formulation of the antibody nimotuzumab
CONC2022/0009693A CO2022009693A2 (es) 2019-12-17 2022-07-11 Formulación estable y de alta concentración del anticuerpo nimotuzumab

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU2019000104A CU20190104A7 (es) 2019-12-17 2019-12-17 Formulación estable del anticuerpo nimotuzumab

Publications (1)

Publication Number Publication Date
CU20190104A7 true CU20190104A7 (es) 2021-08-06

Family

ID=76478863

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2019000104A CU20190104A7 (es) 2019-12-17 2019-12-17 Formulación estable del anticuerpo nimotuzumab

Country Status (12)

Country Link
US (1) US20230018364A1 (es)
EP (1) EP4079294A2 (es)
JP (1) JP7796646B2 (es)
KR (1) KR20220119091A (es)
CN (1) CN114867468A (es)
AU (1) AU2020409887B2 (es)
BR (1) BR112022010488A2 (es)
CA (1) CA3163630A1 (es)
CO (1) CO2022009693A2 (es)
CU (1) CU20190104A7 (es)
MX (1) MX2022007509A (es)
WO (1) WO2021121444A2 (es)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140186361A1 (en) * 2012-09-07 2014-07-03 Coherus Biosciences, Inc. Stable Aqueous Formulations of Adalimumab
WO2005063291A1 (ja) * 2003-12-25 2005-07-14 Kirin Beer Kabushiki Kaisha 抗体を含有する安定な水性医薬製剤
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
JP2009540015A (ja) * 2006-06-14 2009-11-19 イムクローン・リミテッド・ライアビリティ・カンパニー 抗ｅｇｆｒ抗体の凍結乾燥製剤
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
US20110158987A1 (en) 2009-12-29 2011-06-30 F. Hoffmann-Laroche Ag Novel antibody formulation
US9592297B2 (en) * 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
EP3541413A2 (en) * 2016-11-21 2019-09-25 Polpharma Biologics S.A. Aqueous pharmaceutical formulations
CN107898756B (zh) * 2017-12-22 2020-11-20 东曜药业有限公司 一种用于皮下或肌肉注射的高浓度尼妥珠单抗制剂及其制备方法和应用

Also Published As

Publication number Publication date
EP4079294A2 (en) 2022-10-26
BR112022010488A2 (pt) 2022-09-06
KR20220119091A (ko) 2022-08-26
AU2020409887B2 (en) 2024-08-08
CO2022009693A2 (es) 2022-07-19
CA3163630A1 (en) 2021-06-24
US20230018364A1 (en) 2023-01-19
MX2022007509A (es) 2022-07-01
WO2021121444A3 (es) 2022-02-24
JP2023509354A (ja) 2023-03-08
JP7796646B2 (ja) 2026-01-09
CN114867468A (zh) 2022-08-05
AU2020409887A1 (en) 2022-08-11
WO2021121444A2 (es) 2021-06-24

Similar Documents

Publication Publication Date Title
MA47313A (fr) Formulations sous-cutanées d&#39;anticorps her2
CY1126062T1 (el) Σταθερη φαρμακοτεχνικη μορφη anti-ifnar1
CO2023004252A2 (es) Anticuerpos anti-ceacam5 y conjugados y usos de los mismos
CL2021002645A1 (es) Anticuerpos anti-muc16-cd3 biespecíficos y conjugados anti-muc16-fármacos. (divisional de solicitud 201900726)
MX2024007358A (es) Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y metodos para su uso.
PE20211284A1 (es) Anticuerpos anti-nkg2a y usos de los mismos
AR107708A1 (es) Formulaciones de antagonista de il-6 y sus usos
MX2020008075A (es) Anticuerpos anti-ctla4 y métodos para elaborarlos y usarlos.
PE20190975A1 (es) Novela cd47 anticuerpos monoclonales y sus usos
CO2020006865A2 (es) Composiciones y métodos para el agotamiento de células cd5+
CL2016000215A1 (es) Terapia y diagnóstico basado en proteínas de patología mediada por tau en enfermedad de alzheimer (divisional de sol. n° 679-14).
ECSP088753A (es) Terapia tumoral con un anticuerpo contra el factor de crecimiento endotelial vascular y un anticuerpo contra el receptor del factor de crecimiento epitelial tipo 2 humano
ECSP20020949A (es) Conjugados de fármaco-anticuerpo (adc) anti-egfr y sus usos
BR112018076639A2 (pt) quimioterapias de combinação
EA202190102A1 (ru) Коньюгаты антител к тканевым факторам с лекарственным средством и их применение в лечении рака
PE20230682A1 (es) Anticuerpo anti-ox40 y usos del mismo
MX2022007509A (es) Formulacion estable y de alta concentracion del anticuerpo nimotuzumab.
DOP2025000008A (es) Composición farmacéutica de anticuerpo anti-cd20 y uso de la misma
CL2024001536A1 (es) Formulaciones estabilizadas que contienen anticuerpos biespecíficos anti-cd20 x anti-cd3.
MX2021002500A (es) Anticuerpos y secuencias de nucleotidos novedosos, y sus usos.
CL2023003209A1 (es) Composición farmacéutica de pembrolizumab y su uso
ECSP22092205A (es) Composición farmacéutica acuosa de levilimab y su uso
AR119973A1 (es) Composiciones y métodos de anticuerpos anti-cd39
AR132867A1 (es) Anticuerpo monoclonal o fragmento de unión a antígeno del mismo que se une específicamente a axl, y uso del mismo
AR123279A1 (es) Anticuerpos y conjugados anti-ceacam5 y usos de los mismos